NICE refuses to expand use of Roche’s IPF drug Esbriet
admin 12th June 2017 Uncategorised 0The National Institute for Health and Care Excellence (NICE) it remaining steadfast in its position that Roche’s Esbriet should only be funded by the NHS for patients with moderate forms of the fatal lung scarring disease idiopathic pulmonary fibrosis (IPF).
More: NICE refuses to expand use of Roche’s IPF drug Esbriet
Source: News